| Audience | Pain management clinicians, cannabis clinicians, clinical laboratory and toxicology professionals, medical device and diagnostics researchers, and patients curious about how cannabinoid dosing might eventually be measured objectively |
| Primary Topic | A peer-reviewed review comparing conventional analytical methods and emerging biosensor technologies for measuring THC and CBD, with a focus on their potential future role in therapeutic drug monitoring for pain management, published in the Journal of Pharmaceutical and Biomedical Analysis in 2026 |
| Source | Read the review in the Journal of Pharmaceutical and Biomedical Analysis. | Read PDF |
New Review Maps the Race to Build Cannabinoid Biosensors for Pain Management
Cannabinoids are increasingly used for chronic and neuropathic pain, but clinicians still lack a reliable way to measure how much THC or CBD a patient actually has on board, the same kind of monitoring routinely used for many other prescribed drugs. A new review compares conventional lab methods with an emerging generation of portable biosensors built to close that gap, and concludes that while some approaches look promising, none are validated enough for routine clinical use today.
| Study Type | Peer-reviewed narrative review of analytical and biosensor technologies (not a clinical trial) |
| Journal | Journal of Pharmaceutical and Biomedical Analysis |
| Published | 2026 (online ahead of print; December 2026 print issue) | Read PDF |
| Clinical Focus | Measuring THC and CBD concentrations to support therapeutic drug monitoring (TDM) in pain management |
| Conventional Methods Reviewed | Chromatography, mass spectrometry, and spectroscopy |
| Biosensor Platforms Reviewed | Electrochemical sensors, colorimetric sensors, optical and fluorescence-based platforms, immunoassays, novel material-based sensors, and receptor- or cell-based biological methods |
| Comparison Criteria | Target analytes, biological matrices tested, analytical performance, validation status, and clinical feasibility |
| Most Promising Near-Term Platforms | Portable electrochemical sensors and compact optical or immunoassay platforms, per the authors |
| Key Unmet Needs Identified | Validation in authentic patient samples, comparison against reference laboratory methods, improved reproducibility and stability, and stronger links between measured concentration, therapeutic response, and adverse effects |
| Clinical Readiness | Most reported biosensors remain preliminary; none are described as ready for routine clinical therapeutic drug monitoring |
| DOI | 10.1016/j.jpba.2026.117673 |
| PMID | 42551182 |
THC and cannabidiol (CBD) are increasingly explored as options for chronic and neuropathic pain, but the review’s authors point to a structural problem underneath that trend: cannabinoid products vary enormously in formulation, the field has no agreed therapeutic concentration range the way it does for many prescription drugs, and there is not enough concentration-response evidence connecting a measured cannabinoid level to a specific clinical effect.
Without that infrastructure, clinicians cannot do what they routinely do for drugs like lithium or certain anticonvulsants: check a blood level to confirm a patient is in a therapeutic range rather than under- or over-dosed. This review frames closing that gap as a measurement and validation problem first, before it can become a dosing tool.
Conventional analytical methods, chromatography, mass spectrometry, and spectroscopy, can measure cannabinoid concentrations with high precision and are the reference methods the review uses to judge newer technologies against.
Their limitation is practical rather than technical: they require laboratory equipment, trained personnel, and turnaround time that make them impractical for routine, real-time monitoring in a pain clinic or at a patient’s bedside. That gap is what has driven interest in smaller, faster, cheaper biosensor alternatives.
The review catalogs a wide range of biosensor approaches under active development: electrochemical sensors, colorimetric sensors, optical and fluorescence-based platforms, immunoassays, novel material-based sensors, and receptor- or cell-based biological detection methods.
Each platform detects cannabinoids differently and has been tested against different target analytes and biological matrices (such as blood, saliva, or sweat), which is part of why the authors argue the field needs a review that explicitly compares them against the clinical requirements of pain management monitoring rather than treating them as interchangeable lab curiosities.
Among the platforms reviewed, the authors identify portable electrochemical sensors and compact optical or immunoassay platforms as the most promising candidates for near-term translation to point-of-care use, largely because of their combination of portability, speed, and reasonable analytical performance.
That assessment is a relative ranking within an early-stage field, not a claim that any specific device is validated or available for clinical use. The review is explicit that this is a directional signal about where translational effort is most likely to pay off first.
The authors are direct about the gap between a working sensor and a clinically usable tool. Most reported biosensors remain preliminary and still need validation in authentic patient samples rather than spiked laboratory samples, head-to-head comparison against reference analytical methods, and demonstrated reproducibility and stability outside a controlled lab setting.
Most importantly for clinical use, the review calls for stronger evidence directly linking a measured cannabinoid concentration to a patient’s therapeutic response and adverse effects, since a sensor that accurately measures a number is only clinically useful once that number is known to mean something for dosing or safety.
Even a perfectly accurate cannabinoid biosensor would only be as useful as the clinical interpretation behind it. The review’s emphasis on concentration-response evidence reflects a well-known challenge in cannabinoid pharmacology: individual variation in absorption, metabolism, and receptor sensitivity means the same measured blood level can correspond to different effects in different patients.
That is a reason to keep expectations calibrated. This technology, if it matures, would most likely support monitoring and safety, confirming exposure, tracking adherence, or flagging unusually high levels, well before it could function as a precise dosing calculator the way therapeutic drug monitoring does for some other medications.
Therapeutic drug monitoring already shapes prescribing for a range of medications with narrow therapeutic windows or high individual variability in metabolism, from certain antiepileptics to immunosuppressants. Cannabinoid-based pain treatment has expanded without that same infrastructure, leaving clinicians to titrate dose largely by patient-reported response.
This review is best read as an early snapshot of the analytical groundwork that would need to mature before cannabinoid TDM becomes a realistic clinical tool, not as a sign that such monitoring is imminent. Portable, validated biosensors are a genuinely useful long-term goal for safety and personalized dosing, but the authors’ own conclusions place that goal several validation steps away.
As someone who spends a lot of clinical time titrating cannabinoid dosing by symptom response rather than a lab value, I read this review as a useful, honest status report rather than a breakthrough. We do not currently have a reliable way to confirm how much THC or CBD a patient actually has in their system when we are trying to understand why a dose is or is not working, and that is a real gap compared to how we manage many other medications.
What I appreciate about this paper is that it does not oversell the technology. The authors point to portable electrochemical and optical or immunoassay sensors as the most promising near-term candidates, but they are equally clear that most of these tools have not been validated in real patient samples, compared against reference lab methods, or linked to actual clinical outcomes. Until that work is done, a sensor reading would tell us a number, not what to do with it. I would treat this as an early, worthwhile step in building infrastructure that pain management and cannabis medicine genuinely need, not as something ready to change how I counsel or monitor patients today.
How to Read a Technology Review Rather Than a Treatment Study
It is easy to see the words ‘cannabinoid’ and ‘pain management’ in the same abstract and assume a paper is reporting on treatment efficacy.
This review answers a different question entirely: not whether cannabinoids relieve pain, but whether we can currently measure how much cannabinoid is in a patient’s system, and how close the tools for doing that are to clinical readiness.
A Four-Step Reading Frame
Separate the measurement question from the treatment question
This review says nothing about whether cannabinoids work for pain; it is entirely about the tools that could someday measure cannabinoid exposure.
Note that ‘most promising’ is a relative, qualitative judgment
Electrochemical and optical/immunoassay platforms were ranked ahead of other approaches based on the authors’ assessment of current literature, not a statistically compared head-to-head trial.
Track the validation gap explicitly named by the authors
Testing in authentic patient samples, comparison with reference methods, reproducibility, and links to therapeutic response and adverse effects are all still missing.
Hold the clinical distance in view
Even a validated sensor would need further work connecting a measured concentration to a specific clinical meaning before it could guide dosing decisions.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
This Is About Measurement Tools, Not a New Treatment
If you use cannabis for pain, this review does not test whether it works. It surveys the technology being built to eventually measure how much THC or CBD is actually in your system, the way a blood test might check a level of another medication.
That kind of testing is not yet available in routine clinical care. Dosing decisions today still rely on how you report your symptoms and side effects to your clinician.
A Real Gap in Cannabinoid Prescribing Infrastructure
Pain clinicians who incorporate cannabinoids into treatment plans currently lack the objective monitoring tools available for many other prescribed medications, relying instead on patient-reported response and trial-and-error titration.
This review is a useful map of where that infrastructure might eventually come from, but it should not change current practice. No biosensor discussed here is validated for clinical dosing decisions today.
A Structured Comparison Worth Tracking
For laboratory and toxicology professionals, the review’s side-by-side comparison of target analytes, biological matrices, analytical performance, and validation status offers a useful framework for evaluating which biosensor platforms deserve further study.
The explicit call for head-to-head validation against reference methods like chromatography and mass spectrometry is exactly the kind of study that would need to happen before any of these platforms could be trusted for clinical reporting.
Promising Is Doing a Lot of Work in This Review
Describing electrochemical and optical/immunoassay platforms as ‘most promising’ is a qualitative judgment drawn from early-stage, largely lab-based studies, not a demonstrated clinical performance advantage.
Readers should not interpret this review as evidence that point-of-care cannabinoid testing is close to clinical reality. The authors’ own validation gaps, real patient samples, reference-method comparison, reproducibility, suggest the opposite.
A Roadmap for Where Translational Investment Could Pay Off
For researchers and companies developing cannabinoid diagnostics, this review functions as a competitive landscape analysis, identifying which platform types have the most favorable combination of portability, speed, and analytical performance for point-of-care translation.
It also functions as a checklist of unmet requirements, validation in real patient samples, reference-method comparison, reproducibility and stability, and clinical outcome linkage, that any credible product development effort would need to address.
The Field Needs This Infrastructure, But Does Not Have It Yet
Cannabis clinicians manage patients across highly variable products and individual responses, which is exactly the context where objective concentration monitoring would be most valuable for confirming exposure and catching outlier responses.
This review confirms that need is real and being actively researched, while also confirming that no current biosensor technology is ready to inform today’s clinical decisions about cannabinoid dosing for pain.
A Clear Research Agenda, Not Just a Literature Summary
The review does more than catalog existing sensors; it lays out a specific, actionable research agenda: validating biosensors in authentic patient samples, benchmarking them against reference analytical methods, and generating the concentration-response data needed to make a measured cannabinoid level clinically meaningful.
That agenda, particularly the call to link measured concentrations with therapeutic response and adverse effects, is the piece most directly relevant to eventually supporting evidence-based cannabinoid dosing in pain management.
Objective Monitoring Could Eventually Support Safer Cannabinoid Use
A validated, accessible cannabinoid biosensor could eventually help identify unexpectedly high exposure levels, support adherence tracking, and provide an objective complement to self-reported cannabis use, all of which have public health value for safety monitoring.
That potential is a reason to support continued development and validation research, not a reason to describe the technology as available or reliable today. Premature adoption of unvalidated sensors could create false confidence in numbers that do not yet mean what they appear to mean.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
What did this review actually study?
It is a peer-reviewed review, not a clinical trial, that compares conventional analytical methods and emerging biosensor technologies for measuring THC and CBD concentrations, evaluated against the clinical needs of therapeutic drug monitoring in pain management.
Does this review show that cannabinoids work for pain?
No. The review does not evaluate cannabinoid treatment efficacy at all. It is exclusively about the measurement technology needed to eventually monitor cannabinoid levels in patients.
What conventional methods can already measure cannabinoid levels?
Chromatography, mass spectrometry, and spectroscopy can measure cannabinoid concentrations precisely, but they require laboratory equipment, trained staff, and turnaround time that make them impractical for routine point-of-care monitoring.
What new biosensor technologies are being developed?
The review covers electrochemical sensors, colorimetric sensors, optical and fluorescence-based platforms, immunoassays, novel material-based sensors, and receptor- or cell-based biological detection methods.
Which biosensor technologies does the review consider most promising?
Portable electrochemical sensors and compact optical or immunoassay platforms, based on their combination of portability, speed, and analytical performance in current research.
Are any of these biosensors ready for clinical use?
No. The authors state that most reported biosensors remain preliminary and have not been validated in authentic patient samples or compared directly against reference laboratory methods.
What still needs to happen before cannabinoid biosensors could be used clinically?
The review calls for validation in real patient samples, head-to-head comparison with reference analytical methods, improved reproducibility and stability, and stronger evidence linking measured cannabinoid concentrations to therapeutic response and adverse effects.
Why does cannabinoid pain management need this kind of monitoring in the first place?
Unlike many prescribed medications, cannabinoid-based pain treatment lacks agreed therapeutic concentration ranges and sufficient concentration-response data, so clinicians currently rely on patient-reported symptoms rather than objective blood-level monitoring to guide dosing.
Could a future cannabinoid biosensor replace clinical judgment in dosing?
Unlikely on its own. Even a validated sensor would provide a concentration number; individual variation in cannabinoid absorption, metabolism, and receptor sensitivity means that number would still need clinical interpretation rather than functioning as an automatic dosing calculator.
What is the main takeaway for patients using cannabis for pain today?
Objective cannabinoid level testing is not yet part of routine clinical care. Reporting your symptoms, side effects, and response to treatment closely with your clinician remains the primary way dosing is adjusted for now.
